RESEARCH ARTICLE

Percutaneous Vaccination as an Effective Method of Delivery of MVA and MVA-Vectored Vaccines

Clement A. Meseda*, Vajini Atukorale, Jordan Kuhn, Falko Schmeisser, Jerry P. Weir

Division of Viral Products, Center for Biologics Evaluation and Research, US Food & Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993, United States of America

* Clement.Meseda@fda.hhs.gov

Abstract

The robustness of immune responses to an antigen could be dictated by the route of vaccine inoculation. Traditional smallpox vaccines, essentially vaccinia virus strains, that were used in the eradication of smallpox were administered by percutaneous inoculation (skin scarification). The modified vaccinia virus Ankara is licensed as a smallpox vaccine in Europe and Canada and currently undergoing clinical development in the United States. MVA is also being investigated as a vector for the delivery of heterologous genes for prophylactic or therapeutic immunization. Since MVA is replication-deficient, MVA and MVA-vectored vaccines are often inoculated through the intramuscular, intradermal or subcutaneous routes. Vaccine inoculation via the intramuscular, intradermal or subcutaneous routes requires the use of injection needles, and an estimated 10 to 20% of the population of the United States has needle phobia. Following an observation in our laboratory that a replication-deficient recombinant vaccinia virus derived from the New York City Board of Health strain elicited protective immune responses in a mouse model upon inoculation by tail scarification, we investigated whether MVA and MVA recombinants can elicit protective immune responses after percutaneous administration in mouse models. Our data suggest that MVA administered by percutaneous inoculation, elicited vaccinia-specific antibody responses, and protected mice from lethal vaccinia virus challenge, at levels comparable to or better than subcutaneous or intramuscular inoculation. High titered specific neutralizing antibodies were elicited in mice inoculated with a recombinant MVA expressing the herpes simplex type 2 glycoprotein D after scarification. Similarly, a recombinant MVA expressing the hemagglutinin of attenuated influenza virus rgA/Viet Nam/1203/2004 (H5N1) elicited protective immune responses when administered at low doses by scarification. Taken together, our data suggest that MVA and MVA-vectored vaccines inoculated by scarification can elicit protective immune responses that are comparable to subcutaneous vaccination, and may allow for antigen sparing when vaccine supply is limited.

Funding: The work described in this manuscript was supported by intramural research fund provided by the Center for Biologics Evaluation and Research, US Food and Drug Administration.

Competing Interests: The authors have declared that no competing interests exist.
Introduction

The eradication of smallpox, a disease that caused the death of hundreds of millions of people over many centuries, was accomplished primarily by the use of replication-competent vaccinia virus strains as vaccines. Traditional (first-generation) smallpox vaccines, as well as more recently developed cell culture-derived second-generation smallpox vaccines such as ACAM2000 [1,2], the currently licensed smallpox vaccine in the United States, are inoculated into vaccine recipients by scarification of the skin surface, also known as percutaneous, skin or cutaneous vaccination [3]. Rare but severe adverse reactions caused by these vaccines, including generalized vaccinia, eczema vaccinatum, and the more recently recognized cases of myopericarditis [4,5,6,7], limit the use of these vaccines for routine preventative vaccination of the general populace in the absence of any immediate risk of exposure to variola virus (the etiologic agent for smallpox) or other pathogenic orthopoxviruses such as monkeypox virus.

Thus, as early as the 1930s, efforts were made to develop safer smallpox vaccines by attenuating existing strains of vaccinia virus [8,9]. As part of this effort, the modified vaccinia virus Ankara (MVA) was developed in the early 1970s. MVA was derived from the chorioallantois vaccinia virus Ankara (CVA) strain of vaccinia virus, by more than 570 passages in chick embryo fibroblast (CEF) cells [10]. During the course of passage of CVA in CEF cells, several genes (mainly host-range and immunomodulatory genes) were lost, resulting in the severely attenuated MVA. About 15% of the viral genome was lost during passage in CEF cells, and MVA does not replicate productively in most mammalian cells [11,12,13]. MVA has been extensively evaluated in different animal models [14,15,16,17] and in clinical trials, and found to be less reactogenic when compared with replication-competent first and second generation smallpox vaccines [18,19]. MVA is licensed as a smallpox vaccine in Europe and Canada, and currently undergoing clinical development in the United States.

The severe attenuation of MVA and its consequent loss of the capacity to replicate efficiently in mammalian cells is evident in its inability to produce a "vaccine take", a pustular lesion that develops at the inoculation site, when vaccinia virus is inoculated on the skin surface. Apart from its potential use as a smallpox vaccine in immunocompromised individuals, MVA has the capacity to accommodate heterologous DNA, and express encoded proteins, thus serving as a useful viral vector in vaccine development against different types of pathogens. Several recombinant MVA vectors expressing heterologous proteins of different human pathogens are at various phases of clinical development [20,21] Some of the MVA-vectored vaccines in clinical trials include those expressing human immunodeficiency virus antigens [22,23,24], Mycobacterium tuberculosis 85A antigen [25,26,27], malaria antigens [28,29,30], human papilloma virus antigen [31], hepatitis C antigens [32,33], respiratory syncytial virus antigens [34], influenza virus antigens [35,36,37], Epstein-Barr virus antigen [38,39] and more recently, ebola virus antigens [40]. Several other MVA-vectored vaccines have also been evaluated in preclinical studies [41,42,43]. In most preclinical and clinical studies, MVA or recombinant MVA vectors, unlike replication-competent vaccinia virus strains, are inoculated into subjects via the intramuscular, intradermal or subcutaneous routes. Although MVA has been demonstrated to have a better safety profile than replication-competent vaccinia virus, a relatively large inoculum volume of 0.05 to 0.10mL and 0.5 to 1mL of MVA or recombinant MVA is typically used in small animal models and in non-human primates/humans, respectively. This often results in local reactions at the site of inoculation, including muscle ache, pain, and tenderness [44,36]. In addition, the inoculation of prophylactic or therapeutic regimens with needles and syringes can be problematic for some people, a global problem commonly called needle phobia or fear of the needle in common phraseology. Although the use of needle-free injection devices such as the jet injector [45] has become increasingly popular, hypodermic
syringes and needles remain in wide use for the delivery of prophylactic and therapeutic remedies.

Previously, we [46] described a recombinant vaccinia virus, A33R/B5Rko, that was severely attenuated for plaque formation in permissive cell lines due to deletions of the A33R and B5R genes, encoding the A33 and B5 proteins, respectively, of the extracellular virion form of vaccinia virus. The severe attenuation and growth characteristics of the A33/B5Rko virus is reminiscent of the properties of MVA. A33R/B5Rko elicited vaccinia-specific IgG and neutralizing antibodies when BALB/c mice were inoculated by scarification at the base of the tail. In an intranasal challenge model, using the Western Reserve strain of vaccinia virus, the A33R/B5Rko virus conferred comparable levels of protection on mice as those vaccinated with a clonal isolate of Dryvax, DV-3.

During the course of the work above [46], antibody [47] and robust cell-mediated immune responses after the inoculation of recombinant MVA vectors through the skin, were also reported [48,49,50], suggesting that percutaneous inoculation of MVA may elicit equivalent or higher immune responses than subcutaneous injection. In the work described here, we demonstrate in mouse models that percutaneous inoculation of MVA elicited protective immune responses against lethal intranasal challenge with the Western Reserve (WR) strain of vaccinia virus, and at low doses of MVA, lower morbidity was recorded in mice that were vaccinated via the percutaneous route than in those immunized via the intramuscular or subcutaneous routes. In addition, we show in two models that percutaneous inoculation of recombinant MVA expressing heterologous antigens elicited specific immune responses, including neutralizing antibodies, at levels that are comparable to subcutaneous inoculation. A recombinant MVA expressing herpes simplex virus 2 (HSV-2) glycoprotein D elicited gD2-specific IgG and HSV-2 neutralizing antibodies, and a recombinant MVA expressing the hemagglutinin of influenza rgA/Viet Nam/1203/04, H5N1, elicited protective immune responses when inoculated by the percutaneous route. Our data suggest that vaccination via the percutaneous route is efficient in stimulating protective immune responses, and may find clinical relevance in immunizations with MVA and MVA-vectored vaccines.

Materials and Methods

Viruses

The modified vaccinia virus Ankara (MVA; ATCC # VR-1508) was provided by Drs. Linda Wyatt and Bernard Moss (NIAID/NIH) and vaccinia virus strain Western Reserve (VV-WR; ATCC # VR-1354) was provided by Dr. Bernard Moss. We have previously described the construction of a recombinant MVA expressing the herpes simplex virus type 2 glycoprotein D (MVA-gD2), in which the Us6 gene of HSV-2 (strain MS) was inserted into the deletion II region in MVA by homologous recombination [51]. Expression of glycoprotein D is driven by the synthetic vaccinia early/late promoter [52]. Recombinant MVA expressing the hemagglutinin (H5) of influenza virus rgA/Viet Nam/1203/2004 (H5N1) (MVA-HA) was constructed by homologous recombination of the H5 gene into the deletion III region of MVA [53]. Expression of the influenza H5 is driven by the vaccinia H5R promoter. MVA and recombinant MVA vectors were prepared from primary chick embryo fibroblast cells (CEF) or DF-1 cells (ATCC # CRL-12203) that had been infected with the appropriate virus as previously described [54], and partially purified viruses were obtained by passing infected cell lysates through a 36% sucrose cushion. MVA and MVA recombinants were titered on DF-1 cell monolayers. VV-WR was prepared from infected BSC-1 cells (ATCC # CCL-26), and was also partially purified through a 36% sucrose cushion, and titered on BSC-40 cell monolayers (ATCC # CRL-2761). The attenuated influenza virus rgA/Viet Nam/1203/2004 (H5N1) was grown in the allantoic
cavity of embryonated eggs and titrated on MDCK cells. Cells were cultivated and regularly maintained in DMEM containing 10% fetal bovine serum (5% for MDCK cells) and 5μg/mL gentamicin.

Mice
BALB/c mice (4–5 weeks old) were obtained from the Jackson Laboratories, Bar Harbor, Maine. Mice received feed and water freely. The animal study protocol for the work described in this manuscript was approved by the Institutional Animal Care and Use Committee (IACUC) of the Center for Biologics Evaluation and Research, USFDA (CBER/FDA).

Animal inoculation and virus challenge
Intramuscular inoculation into the muscles of the hind legs and subcutaneous inoculation at the base of the tail using 1mL tuberculin syringes affixed with 25-gauge needles, were performed as previously described [17]. Tail scarification of anesthetized animals was also performed as previously described [17]. Briefly, the inoculum was diluted in sterile endotoxin-free phosphate-buffered saline (PBS) such that the desired unit dose is contained per 2μL. Mice were anesthetized by intraperitoneal injection of 1x avertin (2,2,2,-Tribromoethanol in tert- Amyl alcohol (Sigma-Aldrich, St. Louis, Missouri)) diluted in PBS at 20 μL per gram body weight. Using a 25-gauge needle, 15 to 20 needle scratches/puncture were made at the base of the tail and 2μL of the inoculum was applied to the scarified surface.

Vaccinia virus (strain WR) and attenuated influenza A virus (rgA/Viet Nam/1203/2004 (H5N1)), a 6+2 reassortant vaccine strain bases on influenza A/Puerto Rico/8/34, were used in challenge experiments. For intranasal mouse challenge, a dose of ten 50% lethal dose (10 LD50) (equivalent to 1.5 x 10^5 pfu) of VV-WR was used. For challenge with rgA/Viet Nam/1203/2004 (H5N1)), a dose of 10^6 pfu was used. We previously determined this dose to be lethal in our influenza virus challenge model. Mice were anesthetized by intraperitoneal injection of 1x avertin (20 μL per gram body weight), followed by inoculation of the challenge virus in a total of 20 μL suspension into the nares (10 μL per naris) as previously described [17]. Mice were monitored and weighed daily for two weeks post challenge. Mice that lost 25% of their initial body weight were considered to have reached the study endpoint, and were humanely euthanized per the IACUC-approved animal study protocol.

IgG ELISAs and assays for neutralizing antibodies
Testing of antisera for antigen-specific antibodies (IgG) was performed by standard enzyme-linked immunosorbent assay (ELISA). ELISA for vaccinia-specific antibodies was performed using psoralen/UV-inactivated vaccinia virus (Dryvax) as the antigen, as previously described [17]. HSV-2 gD-specific IgG ELISA using partially-purified HSV-2 glycoproteins (50 ng/well) as the antigen, and HSV-2 neutralization assay were performed in 96-well Immulon 2HB plates (Fisher Scientific) and 96-well tissue culture plates (Corning), respectively, as previously described [51]. Influenza virus H5-specific IgG was quantified using Sanoﬁ Pasteur’s inactivated rgA/Viet Nam/1203/2004 vaccine (CBER reference antigen #50) as the coating antigen. Immulon 2HB plates were coated with CBER reference antigen at 1 μg/well, and plates were stored at 4°C overnight. Plates were washed with phosphate-buffered saline containing 0.5% Tween-20 (PBST), and then blocked with PBST containing 10% fetal bovine serum for 2 hours. Subsequent incubation of the antigen with the test serum samples and completion of the assay followed standard ELISA protocol as previously described [51].

Testing of antisera for the neutralization of influenza A virus rgA/Viet Nam/1203/2004 (H5N1), an attenuated vaccine strain generated by reverse genetics, was performed using a
microneutralization assay as previously described [55]. The presence of virus was detected using biotin-conjugated antibody to influenza NP (clone A; Milipore, Billerica, MA, USA) followed by HRP-labeled Streptavidin (KPL, Gaithersburg, MD, USA).

Cytokine assay
Mice were vaccinated with $10^7$ pfu of MVA-gD2 via the subcutaneous or percutaneous route. A control group was vaccinated with $10^7$ pfu of MVA. Seven (7) days after vaccination, mice were euthanized, spleens were collected from dissected mice, and lymphocytes were isolated from spleen homogenates as previously described [51]. Spleen cells were cultured in 24-well tissue culture plates and re-stimulated with live HSV-2 (strain MS) at a multiplicity of infection of 1.0. Culture supernatants were harvested after 48 hours, clarified of cells by centrifugation, and tested for IL-2 and IFN-γ by capture ELISA as described [51], and reagents obtained from BD Pharmingen.

Statistical analysis
Unpaired, two-tailed Student’s t-test for statistical comparison of antibody titers was performed using GraphPad Prism 6.02 software (GraphPad Software, Inc.). The Kaplan-Meier Survival LogRank test was performed using the SigmaPlot 13.0 software (Systat Software, Inc.), and was used to compare differences in the number of surviving animals in the various treatment groups after virus challenge. In all cases, a $p$ value $<0.05$ indicates statistically significant differences between treatment groups.

Results
Percutaneous inoculation of MVA elicits vaccinia-specific antibody responses and protects against VV-WR challenge
In a preliminary experiment to investigate the utility of the percutaneous route for the delivery of MVA, we observed that MVA delivered by tail scarification, while statistically insignificant ($p = 0.298$), elicited a higher vaccinia-specific IgG response and protection in mice than the same dose ($10^6$ pfu) delivered by the intramuscular route (S1 Fig). The experiment using $10^6$ pfu of MVA did not allow us to observe any differences in antibody response, disease progression and protection between the two immunization routes. Thus in subsequent experiments, lower doses of MVA were evaluated.

Groups of mice were vaccinated with $10^5$ pfu of MVA via the intramuscular, subcutaneous, or percutaneous routes. For comparison, a set of three groups of mice were similarly vaccinated with $10^5$ pfu of the licensed ACAM2000 smallpox vaccine, via the same three routes. An untreated group was included as a control. Three weeks after vaccination, serum samples were obtained from all mice and tested for vaccinia-specific antibodies by ELISA, using inactivated Dryvax as the antigen. Among mice in the MVA treatment cohort, an IgG response was detectable in 2/5 mice in the subcutaneous group, and 1/5 in the percutaneous group. The untreated mice and all mice in the MVA intramuscular group had no detectable IgG at this time point. By contrast, all but three mice (2/5 and 1/5 in the intramuscular and subcutaneous groups, respectively) in the ACAM2000 cohort had detectable levels of IgG (Fig 1A). At 4 weeks post-immunization, all mice were challenged intranasally, with a lethal dose ($10 \text{LD}_{50}$) of VV-WR. All mice in the untreated group showed severe symptoms of infection, reaching the study endpoint of 25% weight loss by day 7 post-challenge, and had to be euthanized (Fig 1B & 1C). Except for a mouse in the MVA-intramuscular group, all other mice vaccinated with MVA or ACAM2000, survived. Among the MVA vaccinated animals, mice in the intramuscular group
lost the most weight (Fig 1B), with a mean peak loss of about 16% on day 9 post-challenge. Weight loss among the MVA subcutaneous and percutaneous groups were similar, with peak losses of 9.6% (day 6) and 8.9% (day 7), respectively. However, mice in the MVA percutaneous group recovered more quickly (98.4% of original mean body weight on day 14) than the subcutaneous group (94.4% mean weight on day-14). Among the ACAM2000 treatment groups (Fig 1C), the average peak weight loss was 8.8% (day-5), 7.7% (day-6), and 6.2% (day-6), for the intramuscular, subcutaneous, and percutaneous groups, respectively. In another experiment, mice in groups of five were vaccinated with 10^3 pfu or 10^5 pfu of MVA by scarification. Two other groups were similarly vaccinated with 10^3 pfu or 10^5 pfu of ACAM2000, and a control group was scarified with PBS. Antisera were collected after three weeks and mice were challenged with 10 LD50 of vaccinia virus (strain Western Reserve). Morbidity, as measured by mean weight changes post-challenge, is shown for the MVA treatment groups (B), and for the ACAM2000 treatment groups (C). The "Untreated" control group was the same for both the MVA and ACAM2000 groups. A '+' sign represents a mouse that succumbed to infection.

Table 1. Antibody response and protection after MVA and ACAM2000 inoculation by tail scarification.

| Group          | PBS   | 10^3 pfu MVA | 10^5 pfu MVA | 10^3 pfu ACAM | 10^5 pfu ACAM |
|----------------|-------|--------------|--------------|--------------|--------------|
| Seropositivity | 0/5   | 0/5          | 2/5          | 2/5          | 5/5          |
| Log10 mean IgG titer (± SD) | <LOQ | <LOQ          | 1.36 (± 0.49) | 1.48 (± 0.66) | 2.08 (± 0.16) |
| Survival       | 0/5   | 1/5          | 5/5          | 3/5          | 5/5          |

LOQ = limit of quantitation (0.3 log10); ACAM = ACAM2000 smallpox vaccine. In calculating mean IgG, a log10 titer of 1.0 was assigned to serum samples with no detectable IgG.
5/5 of mice in the ACAM2000 cohort survived VV-WR challenge (Table 1). These sets of data suggest that in this mouse model, MVA inoculation by the percutaneous route elicits equivalent or greater protective immune responses than inoculation via the intramuscular or subcutaneous routes.

**Percutaneous vaccination with recombinant MVA-gD2 elicits HSV-2-specific immune responses**

MVA is an attractive vector being used for the expression of transgenes and has been used in the expression of antigens of a variety of pathogens. Similar to studies investigating MVA as a smallpox vaccine, preclinical and clinical evaluation of MVA vectored vaccines in development has relied predominantly on the use of intramuscular, intradermal or subcutaneous routes of MVA delivery. In order to determine whether the percutaneous route will be useful for the evaluation of MVA vectored recombinant vaccines, a recombinant MVA (MVA-gD2) expressing the glycoprotein D of herpes simplex virus type-2 (HSV-2, strain MS) was evaluated for immunogenicity in the BALB/c mouse model. In this recombinant MVA, the HSV-2 Us6 gene encoding glycoprotein D was inserted into the deletion II site in MVA by homologous recombination [51]. Groups of mice were vaccinated with MVA-gD2 at three dose levels: 10^5 pfu, 10^6 pfu, and 10^7 pfu; with each dose level administered subcutaneously or percutaneously. The control group received 10^7 pfu of MVA subcutaneously. All treatment groups were vaccinated using a prime/boost immunization strategy as previously described [51]. Antisera were collected 3 weeks after the priming vaccination, as well as 3 weeks after the boost, and were tested for HSV-2 specific IgG at both time points, using partially-purified HSV-2 glycoproteins as the antigen (Fig 2A). Antisera collected at the 6-week time point were also tested for HSV-2 neutralizing antibodies (Fig 2B). Antisera obtained from mice vaccinated with the MVA vector had no detectable HSV-2 specific antibodies at both time points. HSV-2 specific antibodies were detected in antisera obtained from mice vaccinated with MVA-gD2 at both time points (Fig 2A). The mean IgG titers (log_{10}) after the priming vaccinations were 1.60 (±0.82 standard deviation (SD)), 2.08 (±0.66 SD), and 2.81 (±0.21 SD), for the 10^5 pfu, 10^6 pfu, and 10^7 pfu, respectively, in the MVA-gD2 subcutaneous cohort. In the three dosage groups vaccinated via the percutaneous route, mean IgG titers (log_{10}) of 2.02 (±0.62 SD), 2.44 (±0.49 SD), and 2.56 (±0.25 SD), were obtained, respectively. Two of five (2/5) mice and a mouse (1/5) in the 10^5 pfu and 10^6 pfu subcutaneous groups, respectively, as well as a mouse (1/5) in the 10^7 pfu percutaneous group did not seroconvert three weeks after the priming vaccination. Higher antibody titers were obtained across the board in all MVA-gD2 groups following booster vaccinations. Thus, at the 6-week time point (i.e., 3 weeks after booster vaccination), mean IgG titers of 2.08 (±1.39 SD), 3.95 (±0.33 SD), and 4.37 (±0.13 SD) were recorded for the 10^5 pfu, 10^6 pfu, and 10^7 pfu, respectively, in the MVA-gD2 subcutaneous cohort. Two of five (2/5) mice in the 10^5 pfu subcutaneous group still failed to seroconvert after booster vaccination. All mice in the percutaneous vaccination groups seroconverted at the 6-week time point. At this time point, the mean IgG titers (log_{10}) for the three percutaneous groups (10^5 pfu, 10^6 pfu, and 10^7 pfu) were 2.87 (±0.45 SD), 3.71 (±0.37 SD), and 4.01 (±0.30 SD), respectively.

The serum samples obtained at the 6-week time point were tested for the ability to neutralize HSV-2 infectivity in Vero cells. Similar to the IgG ELISA result, antisera from the MVA control group did not neutralize HSV-2 (mean serum neutralization (SN) titer was below the level of quantitation of 0.30 log_{10}). Low to modest neutralizing antibody titers were detected in MVA-gD2 vaccinated mice (Table 2).

In the subcutaneous vaccination sub-groups, mean SN titers (log_{10}) of 0.96 (±0.13), 1.08 (±0.46), and 2.41 (±0.43), were obtained for the 10^5 pfu, 10^6 pfu, and 10^7 pfu groups,
Fig 2. Antibody response to MVA-gD2 inoculated by the subcutaneous or percutaneous route. Groups of mice were vaccinated with MVA-gD2 at doses of 10⁵, 10⁶, or 10⁷ pfu, on a prime-boost schedule, with an interval of three weeks between the two vaccinations. A control group was vaccinated with 10⁷ pfu of MVA subcutaneously. Antisera obtained from mice 3 weeks after the first vaccination (week 3) and 3 weeks after the second vaccination (week 6) were tested for HSV-2 gD-specific IgG by ELISA. The log₁₀ values of the mean IgG titers are shown in A. The week-6 antisera were also tested for the neutralization of HSV-2 infectivity in Vero cells. Mean serum neutralization (SN) antibody titers are shown in B. Error bars represent standard deviation.

doi:10.1371/journal.pone.0149364.g002

Table 2. Neutralizing antibody titers and cytokine responses following subcutaneous and percutaneous vaccinations with MVA-gD2.

| Group | 10⁷ MVA | 10⁵ MVA-gD2-SC | 10⁵ MVA-gD2-PC | 10⁶ MVA-gD2-SC | 10⁶ MVA-gD2-PC | 10⁷ MVA-gD2-SC | 10⁷ MVA-gD2-PC |
|-------|---------|----------------|----------------|----------------|----------------|----------------|----------------|
| SN Titer, Log₁₀ (±SD) | <0.30 | 0.96 (±0.13) | 1.38 (±0.34) | 1.08 (±0.46) | 1.44 (±0.25) | 2.41 (±0.43) | 2.47 (±0.49) |
| IL-2 (pg/mL ±SD) | < LOQ | NT | NT | NT | NT | 40.3 (±21) | 52.3 (±40.1) |
| IFN-γ (pg/mL ±SD) | < LOQ | NT | NT | NT | NT | 28.5 (±17.4) | 82.3 (±114.3) |

LOD = limit of quantitation (0.3 log₁₀); SC = subcutaneous; PC = percutaneous; SD = standard deviation; N/A = not applicable.

doi:10.1371/journal.pone.0149364.t002
respectively. The SN titers for the three dosages in the percutaneous groups, were 1.38 (±0.34), 1.44 (±0.25), and 2.47 (±0.49), respectively.

In another experiment, cellular immune response to MVA-gD2 was evaluated. Mice were vaccinated with $10^7$ pfu of MVA subcutaneously, or with $10^2$ pfu of MVA-gD2 either subcutaneously or percutaneously. Spleen cells were harvested from mice 7 days after vaccination and tested for cytokine (IL-2 and IFN-γ) secretion as previously described (Meseda et al., 2002). Spleen cells were re-stimulated in vitro by live infection with HSV-2 (strain MS) at a multiplicity of infection of 1.0. Supernatants were collected from the cultured spleen cells and tested for levels of IL-2 and IFN-γ. Whereas the levels of IL-2 and IFN-γ in the supernatants from the spleen of MVA-infected mice were below detection, all mice in both MVA-gD2 groups had detectable levels of IL-2 and IFN-γ, (Table 2). Mean IL-2 levels of 40.3 ± 21 pg/mL and 52.3 ± 40.1 pg/mL were obtained for the MVA-gD2 subcutaneous and percutaneous groups, respectively. Similarly, IFN-γ levels were 28.5 ± 17.4 pg/mL, and 82.3 ± 114.3 pg/mL, for the subcutaneous and percutaneous MVA-gD2 groups, respectively. Taken together, this set of data suggests that the inoculation of recombinant MVA-gD2 by scarification is capable of eliciting antigen-specific immune responses that are comparable or higher than delivery by subcutaneous inoculation.

Percutaneous vaccination with MVA-HA elicits protective immunity against virus challenge

MVA is used as a vector for the expression of heterologous antigens. The deletion sites in MVA, including the deletion II and deletion III sites, are commonly used for the insertion of transgenes. In order to broaden our understanding of the utility of the percutaneous route for the delivery of MVA-vectored vaccines, we further evaluated a recombinant MVA, MVA-HA, in which the hemagglutinin gene of influenza A virus rgA/Viet Nam/1203/2004 (H5N1), was inserted in the deletion III site of MVA. In a series of experiments, the antibody response following vaccination via the subcutaneous or percutaneous routes was characterized, and the protective effectiveness of vaccination via these routes was evaluated in a mouse intranasal challenge model.

In the first experiment, groups of mice (five per group) were vaccinated with $10^5$, $10^6$, or $10^7$ pfu of MVA-HA on a prime-boost schedule at an interval of 3 weeks between vaccinations. Each dose of MVA-HA was administered via the subcutaneous or percutaneous routes. A control group was vaccinated with $10^7$ pfu of MVA via the subcutaneous route. Three weeks after vaccination, serum samples were obtained from mice and tested for H5-specific IgG, and all mice were challenged with $10^6$ pfu of attenuated influenza rgA/Viet Nam/1203/2004 (H5N1) via the intranasal route. Except for a mouse in the MVA control group that had a low level of non-specific IgG, all other mice in the control group had no H5-specific IgG, and 4/5 (including the one with detectable IgG) succumbed to influenza virus challenge. All mice that were vaccinated with MVA-HA, irrespective of the route, had high levels of H5-specific IgG titers (S2A Fig), and were protected from influenza virus challenge (S2B Fig).

In the second experiment, mice in groups of mice (five per group) were vaccinated with $10^4$, $10^5$, or $10^6$ pfu of MVA-HA via the subcutaneous or percutaneous route on a prime-boost schedule at an interval of 3 weeks between vaccinations. A control group was vaccinated with $10^6$ pfu of MVA, subcutaneously. Antisera were obtained from mice three weeks after the booster vaccination, and all mice were challenged with $10^6$ pfu of influenza rgA/Viet Nam/1203/2004. All mice in the MVA group had no detectable H5-specific IgG. By contrast, all mice inoculated with MVA-HA, irrespective of the dose, had high titers of H5-specific IgG (Fig 3A). The differences in IgG levels between the subcutaneous and percutaneous cohorts at each dose
level of MVA-HA were not statistically significant, although mean IgG titers were slightly higher in the subcutaneous cohort. Following intranasal challenge with influenza rgA/Viet Nam/1203/2004, all mice in the MVA group succumbed to infection, and all mice vaccinated with MVA-HA, irrespective of the dose, survived with varying degrees of morbidity. Among MVA-HA vaccinated mice, the 10^4 pfu/subcutaneous group recorded the severest weight loss (Fig 3B), and the difference in weight changes between the subcutaneous and percutaneous groups vaccinated with 10^4 pfu was statistically significant (two-tailed p-value = <0.001).

A summary of the neutralizing antibody titers of pooled antisera for each treatment group from the two MVA-HA experiments described above is presented in Table 3. The MVA control group had no detectable neutralizing antibody in the serum samples obtained at any time point. Among the groups vaccinated with MVA-HA, neutralizing antibody was below detection in post-prime antisera, except in the 10^7 pfu/subcutaneous group where a titer of 10 was obtained. However, following the administration of booster inoculations, all MVA-HA treatment groups had detectable levels of neutralizing antibody that increased with increase in vaccine dose.

Neutralizing antibody titers in mice in the subcutaneous cohort were 15, 40, and 80, for the 10^4, 10^5, and 10^6 pfu, respectively. Similarly, neutralizing antibody titers among the percutaneous cohort were 15, 60, and 80, for the 10^4, 10^5, and 10^6 pfu, respectively. Interestingly, the levels of neutralizing antibody for the percutaneous treatment groups were similar to the subcutaneous group at the same MVA-HA dosage, in spite of slightly higher total H5-specific
IgG levels in the subcutaneous cohort (difference is not statistically significant). This set of data suggests that the antibody response, both total IgG and neutralizing antibodies, elicited by MVA-HA was comparable between mice that were inoculated via the subcutaneous route and those inoculated via the percutaneous route. Further, we observed that all mice inoculated with $10^4$ pfu of MVA-HA by prime-boost, were protected from influenza virus challenge.

**Discrimination of the protective effectiveness of MVA-HA inoculated via the subcutaneous or percutaneous routes**

In the experiments with MVA-HA described above, all mice that were vaccinated on a prime-boost schedule with $\geq 10^4$ pfu of MVA-HA elicited antibody responses and protection that were indistinguishable between subcutaneous and percutaneous treatment cohorts. In order to further scrutinize the differences between the two inoculation routes, lower doses of MVA-HA were used in experiments. In one experiment, groups of mice (five per group) were vaccinated with MVA-HA at doses of $10^2$, $10^3$ or $10^4$ pfu, each dose administered via the subcutaneous or percutaneous route. A control group was inoculated subcutaneously with $10^4$ pfu of MVA. Booster inoculations in the same amount of MVA-HA or MVA were administered three weeks after mice were primed. At three weeks after the booster doses, mice were challenged with attenuated rgA/Viet Nam/1203/2004, at $10^6$ pfu per mouse, and were evaluated daily for two weeks after mice were primed. At three weeks after the booster doses, mice were challenged with attenuated rgA/Viet Nam/1203/2004, at $10^6$ pfu per mouse, and were evaluated daily for two weeks as described above. None of the animals vaccinated with MVA survived. All mice vaccinated with $\geq 10^3$ pfu MVA-HA in this prime/boost schedule survived. In the $10^2$ pfu MVA-HA group, 2/5 and 1/5 survived in the subcutaneous and percutaneous groups, respectively. Influenza virus pathogenesis in these mice, as measured by weight loss (Fig 4) shows a dose-response with respect to MVA-HA, with weight loss being inversely proportional to the dose of MVA-HA. There were no major differences in survival rates between mice in the subcutaneous and percutaneous groups inoculated with the same dose of MVA-HA. At $10^2$ pfu of MVA-HA, the mean weight loss was higher in the percutaneous group than the subcutaneous group, but the difference was not statistically significant (two-tailed p-value = 0.084).

| Treatment (pfu) | Serum Neutralization Titer |
|----------------|---------------------------|
|                | E1-post dose 1 | E1-post dose 2 | E2-post dose 2 |
| $10^6$ MVA—SC | N/A           | N/A           | < 10          |
| $10^7$ MVA—SC | NT            | < 10          | N/A           |
| $10^4$ MVA-HA—SC | N/A       | N/A           | 10            |
| $10^4$ MVA-HA—PC | N/A      | N/A           | 20            |
| $10^6$ MVA-HA—SC | < 10      | 15            | 40            |
| $10^5$ MVA-HA—PC | < 10      | 15            | 20            |
| $10^6$ MVA-HA—SC | < 10      | 40            | 60            |
| $10^5$ MVA-HA—PC | < 10      | 60            | 40            |
| $10^6$ MVA-HA—SC | 10        | 80            | N/A           |
| $10^7$ MVA-HA—PC | < 10      | 80            | N/A           |

NT = Not tested; N/A = not applicable; E1-post dose 1 = experiment 1, post prime antisera; E1-post dose 2 = experiment 1, post boost antisera; E2-post dose 2 = experiment 2 post boost antisera; *titer represents the average of two repeat testing.

For each treatment group, serum samples (5 per group) were pooled for neutralization test.

For each treatment group, serum samples (5 per group) were pooled for neutralization test.

**Table 3. Neutralizing antibody titers against the H5 of attenuated influenza rgA/Viet Nam/1203/2004, H5N1 virus.**

| Treatment (pfu) | Serum Neutralization Titer |
|----------------|---------------------------|
|                | E1-post dose 1 | E1-post dose 2 | E2-post dose 2 |
| $10^6$ MVA—SC | N/A           | N/A           | < 10          |
| $10^7$ MVA—SC | NT            | < 10          | N/A           |
| $10^4$ MVA-HA—SC | N/A       | N/A           | 10            |
| $10^4$ MVA-HA—PC | N/A      | N/A           | 20            |
| $10^6$ MVA-HA—SC | < 10      | 15            | 40            |
| $10^5$ MVA-HA—PC | < 10      | 15            | 20            |
| $10^6$ MVA-HA—SC | < 10      | 40            | 60            |
| $10^5$ MVA-HA—PC | < 10      | 60            | 40            |
| $10^6$ MVA-HA—SC | 10        | 80            | N/A           |
| $10^7$ MVA-HA—PC | < 10      | 80            | N/A           |

NT = Not tested; N/A = not applicable; E1-post dose 1 = experiment 1, post prime antisera; E1-post dose 2 = experiment 1, post boost antisera; E2-post dose 2 = experiment 2 post boost antisera; *titer represents the average of two repeat testing.

For each treatment group, serum samples (5 per group) were pooled for neutralization test.

**Table 3. Neutralizing antibody titers against the H5 of attenuated influenza rgA/Viet Nam/1203/2004, H5N1 virus.**

| Treatment (pfu) | Serum Neutralization Titer |
|----------------|---------------------------|
|                | E1-post dose 1 | E1-post dose 2 | E2-post dose 2 |
| $10^6$ MVA—SC | N/A           | N/A           | < 10          |
| $10^7$ MVA—SC | NT            | < 10          | N/A           |
| $10^4$ MVA-HA—SC | N/A       | N/A           | 10            |
| $10^4$ MVA-HA—PC | N/A      | N/A           | 20            |
| $10^6$ MVA-HA—SC | < 10      | 15            | 40            |
| $10^5$ MVA-HA—PC | < 10      | 15            | 20            |
| $10^6$ MVA-HA—SC | < 10      | 40            | 60            |
| $10^5$ MVA-HA—PC | < 10      | 60            | 40            |
| $10^6$ MVA-HA—SC | 10        | 80            | N/A           |
| $10^7$ MVA-HA—PC | < 10      | 80            | N/A           |

NT = Not tested; N/A = not applicable; E1-post dose 1 = experiment 1, post prime antisera; E1-post dose 2 = experiment 1, post boost antisera; E2-post dose 2 = experiment 2 post boost antisera; *titer represents the average of two repeat testing.

For each treatment group, serum samples (5 per group) were pooled for neutralization test.

**Table 3. Neutralizing antibody titers against the H5 of attenuated influenza rgA/Viet Nam/1203/2004, H5N1 virus.**

| Treatment (pfu) | Serum Neutralization Titer |
|----------------|---------------------------|
|                | E1-post dose 1 | E1-post dose 2 | E2-post dose 2 |
| $10^6$ MVA—SC | N/A           | N/A           | < 10          |
| $10^7$ MVA—SC | NT            | < 10          | N/A           |
| $10^4$ MVA-HA—SC | N/A       | N/A           | 10            |
| $10^4$ MVA-HA—PC | N/A      | N/A           | 20            |
| $10^6$ MVA-HA—SC | < 10      | 15            | 40            |
| $10^5$ MVA-HA—PC | < 10      | 15            | 20            |
| $10^6$ MVA-HA—SC | < 10      | 40            | 60            |
| $10^5$ MVA-HA—PC | < 10      | 60            | 40            |
| $10^6$ MVA-HA—SC | 10        | 80            | N/A           |
| $10^7$ MVA-HA—PC | < 10      | 80            | N/A           |

NT = Not tested; N/A = not applicable; E1-post dose 1 = experiment 1, post prime antisera; E1-post dose 2 = experiment 1, post boost antisera; E2-post dose 2 = experiment 2 post boost antisera; *titer represents the average of two repeat testing.

For each treatment group, serum samples (5 per group) were pooled for neutralization test.

doi:10.1371/journal.pone.0149364.t003

Percutaneous Vaccination with MVA
Finally, in two independent experiments, mice in groups of five in each experiment were vaccinated with low doses of MVA-HA that were administered once, and were challenged three weeks after vaccination. Groups of mice were inoculated at doses of $10^2$, $10^3$, or $10^4$ pfu of MVA-HA subcutaneously or percutaneously. Control groups received $10^4$ pfu of MVA subcutaneously. A summary of the number of surviving mice is presented in Table 4. None of the mice vaccinated with MVA survived. Among mice in the MVA-HA subcutaneous vaccination cohort, 3/10, 5/10, and 8/10 survived in the $10^2$ pfu, $10^3$ pfu, and $10^4$ pfu vaccination groups, respectively. Similarly, among mice in the percutaneous vaccination cohort, 5/10, 6/10, and 8/10 survived viral challenge. The mean weight loss among mice in these experiments are shown in Fig 5. Statistical comparisons of the number of surviving mice show that differences in survival between mice that were vaccinated with $10^4$ pfu of MVA-HA (irrespective of vaccination route) were significant.

![Fig 4. Evaluation of vaccination routes by low dose treatment with MVA-HA.](image)

Mice in groups of 5 were vaccinated with MVA or MVA-HA at the doses indicated in the legend. Booster vaccinations were administered after 3 weeks, and mice were challenged with $10^6$ pfu of influenza rgA/Viet Nam/1203/2004 (H5N1), three weeks after the second vaccination. Mice were weighed for 14 days post challenge. Weight loss as a measure of disease severity is shown in A, and the proportion of surviving animals in the different treatment groups are represented in B.

Table 4. Protection of mice following single dose percutaneous or subcutaneous vaccination with MVA-HA.

| Group          | A, B, C | B, D | C, D | D, E | E, F | F, G |
|----------------|---------|------|------|------|------|------|
| Treatment      | $10^4$ MVA | $10^2$ MVA-HA-SC | $10^2$ MVA-HA-PC | $10^3$ MVA-HA-SC | $10^3$ MVA-HA-PC | $10^4$ MVA-HA-SC | $10^4$ MVA-HA-PC |
| Total No. of Mice | 10      | 10   | 10   | 10   | 10   | 10   | 10   |
| No. of Survivors | 0       | 3    | 5    | 5    | 6    | 8    | 8    |

$^a$group A vs B, $p = 0.726$;
$^b$group A vs F, $p = 0.029$;
$^c$group A vs G, $p = 0.019$;
$^d$group B vs C, $p = 0.563$
route) and the MVA control group, were statistically significant (Table 4). However, a comparison of the observed differences in survival between the percutaneous and subcutaneous groups at the $10^2$ pfu dose level indicates the difference is not statistically significant. This set of data suggests that even at low vaccination doses, differences between mouse groups vaccinated via the subcutaneous and percutaneous routes are not apparent in this challenge model.

Discussion

The modified vaccinia virus Ankara (MVA) is licensed in Europe and Canada as a third generation smallpox vaccine, and currently in clinical development for licensure in the United States. The relatively better safety record of MVA compared to first and second generation smallpox vaccines is well documented. This, in addition to its large capacity to accommodate heterologous genes, express encoded proteins, and elicit both humoral and cell-mediated immune responses also makes MVA an attractive vector for the delivery of several candidate vaccines for a variety of infectious and non-infectious human and veterinary diseases [56,57,58,59,60]. Evidence for the delivery of antigens through the skin in Asia dates back to the 1500s with the practice of variolation and continued with the advent of the smallpox vaccine in the late 18th century [3]. Thus replication-competent smallpox vaccines, including those that were used in the successful eradication of smallpox, such as Dryvax, Lister, LIVP, Temple of Heaven, and EM-63, were mostly administered by skin scarification [61]. The current US-licensed second-generation smallpox vaccine, ACAM2000, is also administered by skin scarification, a procedure that is believed to be partly responsible for the success of the global eradication of smallpox by provoking robust innate and adaptive immune responses [62].

Due to the severe attenuation of MVA, as epitomized by its inability to replicate productively in many mammalian cells [11,12,13], MVA and MVA-vectored vaccines are usually administered via routes other than percutaneous in preclinical studies. Clinical investigations of MVA-vectored vaccines have mostly used intramuscular [23,34,35,36] and intradermal routes [38,39], and to a lesser extent, the subcutaneous injection route [63]. Local reactogenicity following vaccination with MVA or MVA-vectored vaccines is believed to be more severe with subcutaneous and intradermal inoculations than via intramuscular route [37,63,64]. In a comparison of the safety and immunogenicity of an MVA-vectored HIV vaccine, individuals vaccinated with MVA.HIVA by the subcutaneous and intradermal routes were found to develop more severe local reactions than those vaccinated via the intramuscular route [63].
However, intramuscular and subcutaneous tissues have relatively fewer antigen presenting cells than the skin tissue and may not be adequate for optimal immune responses [65].

Administering vaccines against infectious diseases through the skin has generated significant interest in recent years, including its use in the delivery of the BCG tuberculosis vaccine [66], and has been further boosted by the development of the microneedle patch technology, which delivers vaccines intradermally. Microneedle inoculation of vaccines has been used in preclinical evaluation of several vaccines, including inactivated polio vaccine [67], influenza vaccine [68,69,70], and measles vaccine [71]. Clinical application of vaccines to the skin has also been documented for a number of vaccines, including influenza vaccine [72,73], and rabies vaccine [74]. Recent studies have suggested that vaccine delivery through the skin takes advantage of the abundant presence of skin-resident antigen-presenting cells, including different subsets of dendritic cells and Langerhans cells, as well as infiltrating antigen presenting cells, to provoke robust immune responses that include both humoral and cell-mediated immune responses [65], and induce long-lived CD8+ T cell memory [75,76]. Moreover, data on the delivery of different types of vaccines through the skin suggest that both live vaccines and subunit vaccines can be administered through the skin, with successful immunization outcomes [67–71,73,74].

Earlier data from our laboratory [17] as well as from clinical trials [57,77] suggest that delivery of the modified vaccinia virus Ankara into the intradermal layer of the skin elicited robust immune responses that were higher than intramuscular or subcutaneous inoculations, and protected mice from intranasal challenge with vaccinia virus [17]. We further showed that a severely attenuated recombinant vaccinia virus that fails to form visible plaques in several mammalian cell lines, reminiscent of MVA, elicited protective immune responses when used to vaccinate mice by scarification [46]. In the work described here, we expanded our investigation on the delivery of MVA as well as MVA-vectored antigens through the skin. In a preliminary experiment, we observed that IgG titers were higher in mice that received 10^6 pfu of MVA by skin scarification than in mice that received the same dose of MVA by intramuscular inoculation. In subsequent experiments, antibody responses and protection of mice that were vaccinated with MVA subcutaneously or by tail scarification were higher than in those vaccinated via the intramuscular route. Melamed et al. [47] compared the antibody response elicited in response to MVA and two recombinant MVAs that had been genetically modified to replicate in Vero and BSC-1 cells, after inoculating mice by intramuscular injection or tail scarification. Their data indicate that tail scarification was efficient at inducing an antibody response, although the intramuscular route elicited higher geometric mean titers of antibody and conferred higher survival rates. The difference between their observation and the one reported here may be due to differences in experimental procedures and/or assay methods. For instance, in our work, MVA for tail scarification is typically in 2 μL volume per dose, making it easier to handle than the 10μL used by Melamed et al [47]. In subsequent experiments, the route comparison was limited to subcutaneous versus percutaneous routes, since the subcutaneous route is more commonly used in vaccination studies of MVA vectors. As the utility of MVA as a viral vector for the expression of heterologous antigens is expanding [22–40,78], we also compared the antibody responses and protection conferred by vaccination with two MVA recombinants, one expressing the HSV-2 glycoprotein D, and the other expressing the H5 hemagglutinin of influenza virus rg/A Viet Nam/1203/2004 (H5N1).

Mice that were vaccinated with MVA-gD2 by tail scarification, elicited higher than or similar titers of HSV-2 gD2-specific IgG and neutralizing antibodies to those vaccinated by subcutaneous inoculation. The observed differences in IgG titers were not statistically significant between the two routes at 10^6 or 10^7 pfu, but were statistically significant at 10^5 pfu, suggesting that the percutaneous delivery of MVA-gD2 may be more effective than subcutaneous
inoculation in eliciting HSV-2 neutralizing antibodies at lower vaccine doses. Consistent with previous reports [48,49], percutaneous inoculation of MVA-gD2 also elicited cell-mediated immune responses, as evident in the secretion of IFN-γ and IL-2 by re-stimulated immune splenocytes.

MVA vectors expressing influenza antigens have been shown to elicit protective immune responses in animal models [79], including mice [80–83], ferrets [84] and macaques [85,86]. In the second recombinant MVA vaccine model, MVA-HA, expressing influenza virus H5, was used to vaccinate mice by subcutaneous injection or by tail scarification, and the H5-specific antibody response and protective effectiveness against intranasal challenge with the homologous attenuated influenza virus rgA/Viet Nam/1203/2004, were assessed. The data indicate that comparable levels of antibody titers and protection were conferred by the two immunization routes. Interestingly, higher survival rates among mice vaccinated by tail scarification were recorded at low vaccine doses. Among the advantages attributed to skin delivery of vaccines is the possibility of antigen dose sparing [70,72]. The data described in this manuscript support these earlier reports as lower doses of MVA or MVA-gD2 or MVA-HA were found to elicits full or partial protection of mice.

In summary, we showed that MVA, and recombinant MVA vectors expressing HSV-2 gD2 or influenza virus H5 elicited protective immune responses in the mouse model. Taken together, the data presented in this work suggest that MVA and MVA-vectored vaccines can be effective when delivered through the skin. With the advantage that antigen delivery to the skin requires a volume that is at least 25 times (in murine models) to 200 times (in humans) less than the volume used in subcutaneous vaccination, a more comprehensive investigation of the clinical benefit of delivering MVA and MVA-vectored vaccines through the skin is necessary. Apart from its efficiency in provoking robust immune responses, it may also help to ameliorate or obliterate some of the commonly reported volume-related local reactions associated with subcutaneous or intramuscular vaccine delivery, such as pain at the site of injection, and may be more acceptable in people with needle phobia, thus enhancing compliance with scheduled immunization programs. Although the preclinical evaluation of vaccines by skin scarification, as described in our study, involves the use of improvised needles for the scarification process prior to the application of vaccines, advances in the development of the microneedle patch [87,88,89] should facilitate painless application of vaccines to the skin without the use of hypodermic injection needles or the bifurcated needle used in administering smallpox vaccines. In preclinical studies, microneedle delivery of MVA-vectored vaccines has been shown to be effective in eliciting robust immune responses against malaria [90] that are comparable to the levels attained by intradermal vaccination. Thus with further refinement, the use of microneedle delivery appears to hold a promising future for the application of viral-vectored vaccines through the skin.

Supporting Information

S1 Fig. IgG response to MVA inoculated intramuscularly or by tail scarification. Mice in groups of five were vaccinated with 10^6 pfu of MVA via the intramuscular route (IM) or by tail scarification (PC). Serum samples obtained at day-5, day-13, day-20, and day-27 post-vaccination, were tested for vaccinia-specific IgG by ELISA (A). Each data point represents the mean OD_{405} value for the five mice in each treatment group. Error bar represents the standard deviation. At four weeks post-vaccination, mice were challenged with 25 LD_{50} of VV-WR, intranasally. The percentages of surviving mice are shown (B).

S2 Fig. IgG response to MVA-HA and protection of vaccinated mice. Mice (5 per group) were vaccinated subcutaneously or percutaneously with 10^5, 10^6, or 10^7 pfu of MVA-HA by
prime-boost at an interval of 3 weeks between vaccinations. A control group received $10^7$ pfu of MVA prime-boost, subcutaneously. Serum samples obtained 3 weeks after priming (week-3) and 3 weeks after boosting (week-6) were tested for H5-specific IgG (A). Error bars represent standard deviation. Mice were subsequently challenged with $10^6$ pfu of influenza rgA/Viet Nam/1203/2004, and weighed daily for two weeks (B). A “+” sign represents a mouse that succumbed to infection.

Acknowledgments

The authors wish to thank Drs. Bernard Moss and Linda Wyatt, NIAID/NIH, for the MVA and VV-WR viruses. We also thank Dr. Maryna Eichelberger and Dr. Alonzo Garcia, CBER/FDA, for reviewing this manuscript. This work was supported by intramural research funds from CBER/FDA.

Disclaimer: All opinions expressed in this article are solely those of the authors, and are neither meant to imply nor do they imply any official position of the US Food and Drug Administration, and therefore do not bind or obligate the Agency.

Abstract presented in part at the 115th General Meeting of the American Society for Microbiology, New Orleans, Louisiana, USA, May 30 – June 2, 2015.

Author Contributions

Conceived and designed the experiments: CAM JPW. Performed the experiments: CAM VA JK FS. Analyzed the data: CAM VA FS JPW. Contributed reagents/materials/analysis tools: CAM VA JK FS JPW. Wrote the paper: CAM VA FS JPW.

References

1. Monath TP, Caldwell JR, Mundt W, Fusco J, Johnson CS, Buller M et al. ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain)—a second-generation smallpox vaccine for biological defense. Int J Infect Dis 2004; 8 Suppl 2: S31–44. PMID: 15491873
2. Greenberg RN, Kennedy JS. ACAM2000: a newly licensed cell culture-based live vaccinia smallpox vaccine. Expert Opin Investig Drugs 2008; 17: 555–64. doi:10.1517/13543784.17.4.555 PMID: 18363519
3. Weniger BG, Glenn GM. Cutaneous vaccination: antigen delivery into or onto the skin. Vaccine 2013; 31: 3389–91. doi: 10.1016/j.vaccine.2013.05.048 PMID: 23684830
4. Centers for Disease Control and Prevention (CDC). Cardiac adverse events following smallpox vaccination—United States, 2003. MMWR 2003; 52: 248–250. PMID: 12880519
5. Halsell JS, Riddle JR, Atwood JE, Gardner P, Shope R, Poland GA et al. Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel. JAMA 2003; 289: 3283–89. PMID: 12824210
6. Eckart RE, Love SS, Atwood JE, Arness MK, Cassimatis DC, Campbell C, et al. Incidence and follow-up of inflammatory cardiac complications after smallpox vaccination. J Am Coll Cardiol 2004; 44: 201–5. PMID: 15234435
7. Bruner DI, Butler BS. Smallpox vaccination-associated myopericarditis is more common with the newest smallpox vaccine. J Emerg Med 2014; 46: e85–7. doi: 10.1016/j.jemermed.2013.06.001 PMID: 23993935
8. Rivers TM, Ward SM. Jennerian prophylaxis by means of intradermal injections of culture vaccine virus. J Exp Med 1935; 62: 549–60. PMID: 19870435
9. Stickl HA. Smallpox vaccination and its consequences: first experiences with the highly attenuated smallpox vaccine MVA. Prev Med 1974; 3: 97–101. PMID: 4205586
10. Mayr A, Stickl H, Muller HK, Danner K, Singer H. [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)]. Zentralbl Bakteriol B 1978; 167(5–6): 375–90. PMID: 219640
11. Blanchard TJ, Alcami A, Andrea P, Smith GL. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J Gen Virol 1998; 79: 1159–67. PMID: 9603331

12. Carroll MW, Moss B. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 1997; 238: 198–211. PMID: 9400593

13. Drexler I, Keller K, Wahren B, Errie V, Sutter G. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J Gen Virol 1998; 79: 347–52. PMID: 9472619

14. Wyatt LS, Earl PL, Eller LA, Moss B. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc Natl Acad Sci U S A 2004; 101: 4590–95. PMID: 15070672

15. Earl P, Americo JL, Wyatt LS, Eller LA, Whitbeck JC, Cohen GH, et al. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature 2004; 428: 182–5. PMID: 15014500

16. Stittelaar KJ, van Amerongen G, KondoVA I, Kuiken T, van Lavieren RF, Pistor FH et al. Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus. J Virol. 2005; 79:7845–51. PMID: 15919938

17. Meseda CA, Garcia AD, Kumar A, Mayer AE, Manischewitz J, King LR, et al. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model. Virology 2005; 339: 164–75. PMID: 15993917

18. Walsh SR, Wilck MB, Dominguez DJ, Zablowsky E, Bajimaya S, Gagne LS, et al. Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial. J Infect Dis 2013; 207: 1888–97. doi: 10.1093/infdis/jit105 PMID: 23482644

19. Overton ET, Stapleton J, Frank I, Hassler S, Goepfert PA, Barker D, et al. Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial. Open Forum Infect Dis 2015; 2(2):ofv040. doi: 10.1093/ofid/ofv040 PMID: 26380340

20. Boukhebza H, Bellon N, Limacher JM, Inchauspé G. Therapeutic vaccination to treat chronic infectious diseases: Current clinical developments using MVA-based vaccines. Hum Vaccin Immunother 2012, 8: 1746–57. doi: 10.4161/hv.21689 PMID: 22894957

21. Verheust C, Goossens M, Pauwels K, Breyer D. Biosafety aspects of modified vaccinia virus Ankara (MVA)-based vectors used for gene therapy or vaccination. Vaccine. 2012; 30: 2623–32. PMID: 22342706

22. Garcia FJ, Bermalde de Quiros JC, Gomez CE, Perdiguer O, Najera JL, Jimenez V, et al. Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02). Vaccine 2011; 29: 8309–16. PMID: 21907749

23. Mehendale SM, Thakar M, Sahay S, Kumar M, Shete A, Sathyamurthi P, et al. Safety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: a phase I randomised Trial in HIV-uninfected Indian volunteers. PLoS One 2013; 8: e55831. doi: 10.1371/journal.pone.0055831 PMID: 23418465

24. Njuguna IN, Ambler G, Reilly M, Ondondo B, Kanyugo M, Lohman-Payne B, et al. PedVacc 002: A phase III randomized clinical trial of MVA.HIVa vaccine administered to infants born to human immunodeficiency virus type 1-positive mothers in Nairobi. Vaccine 2014; 32: 5801–08. doi: 10.1016/j.vaccine.2014.08.034 PMID: 25173484

25. Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013; 381: 1021–8. PMID: 23391465

26. Satti I, Meyer J, Harris SA, Mnajlay Thomas ZR, Griffiths K, Antrobus RD, et al. Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial. Lancet Infect Dis 2014; 14: 939–46. doi: 10.1016/S1473-3099(14)70845-X PMID: 25151225

27. Ndiaye BP, Thiennemann F, Ota M, Landry BS, Camara M, Diaye S, et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial. Lancet Respir Med 2015; 3: 190–200. doi: 10.1016/S2213-2600(15)00037-5 PMID: 25726088
28. de Barra E, Hodgson SH, Ewer KJ, Bliss CM, Hennigan K, Collins A et al. A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS. PLoS One 2014: 9: e115161. doi: 10.1371/journal.pone.0115161 PMID: 25522180

29. Porter DW, Thompson FM, Berthoud TK, Hutchings CL, Andrews L, Biswas S, et al. A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine. Vaccine 2011; 29: 7514–22. doi: 10.1016/j.vaccine.2011.03.083 PMID: 21501642

30. Hodgson SH, Ewer KJ, Bliss CM, Edwards NJ, Rampling T, Anagnostou NA et al. Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals. J Infect Dis. 2015; 211: 1076–86. doi: 10.1093/infdis/jiu579 PMID: 25336730

31. Rosales R, Rosales C. Immune therapy for human papillomaviruses-related cancers. World J Clin Oncol 2014; 5: 1002–19. doi: 10.5306/wjco.v5.i5.1002 PMID: 25493236

32. Swadling L, Capone S, Antrobus RD, Brown A, Richardson R, Newell EW, et al. A human vaccine strategy based on chimpanzee adenoaviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Sci Transl Med 2014; 6: 261ra153. doi: 10.1126/scitranslmed.3009185 PMID: 25378645

33. Di Bisceglie AM, Janczweska-Kazek E, Habersetzer F, Mazur W, Stanciu C, Carreno V, et al. Efficacy of immunotherapy with TG4040, peg-interferon, and ribavirin in a Phase 2 study of patients with chronic HCV infection. Gastroenterology. 2014; 147: 119–131 doi: 10.1053/j.gastro.2014.03.007 PMID: 24657484

34. Green CA, Scarselli E, Voysey M, Capone S, Vitelli A, Nicosia A, et al. Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (Parad3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phase 1 clinical trial in healthy adults. BMJ Open 2014; 5: e008748. doi: 10.1136/bmjopen-2015-008748 PMID: 26510727

35. Antrobus RD, Lillie PJ, Berthoud TK, Spencer AJ, McLaren JE, Ladell K, et al. A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years. PLoS One 2012; 7: e48322. doi: 10.1371/journal.pone.0048322 PMID: 23118984

36. Kreijtz JH, Goeijenbier M, Moesker FM, van den Dries L, Goeijenbier S, De Gruyter HL, et al. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial. Lancet Infect Dis 2014; 14: 1196–207. doi: 10.1016/S1473-3099(14)70963-6 PMID: 25455987

37. Tapia MD, Sow SO, Lyke KE, Haidara FC, Diallo F, Doumbia M, et al. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase I trial in UK patients with EBV-positive cancer. Clin Cancer Res 2014; 20: 5009–22. doi: 10.1158/1078-0432.CCR-14-1122-T PMID: 25124688

38. Hui EP, Taylor GS, Jia H, Ma BB, Chan SL, Ho R, et al. Phase I trial of recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer. Clin Cancer Res 2014; 20: 5009–22. doi: 10.1158/1078-0432.CCR-14-1122-T PMID: 25124688

39. Longley RJ, Salman AM, Cottingham MG, Ewer K, Janse CJ, Khan SM, et al. Comparative assessment of vaccine vectors encoding ten malaria antigens identifies two protective liver-stage candidates. Sci Rep 2015; 5: 11820. doi: 10.1038/srep11820 PMID: 26139288
44. Vollmar J, Arndtz N, Eck KM, Thomensen T, Petzold B, Mateo L, et al. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vaccine 2006; 24: 2065–70. PMID:16337719
45. Giudice EL, Campbell JD. Needle-free vaccine delivery. Adv Drug Deliv Rev 2006; 58: 68–89. PMID:16564111
46. Meseda CA, Campbell J, Kumar A, Garcia AD, Merchlinsky M, Weir JP. Effect of the deletion of genes encoding proteins of the extracellular virion form of vaccinia virus on vaccine immunogenicity and protective effectiveness in the mouse model. PLoS One 2013; 8: e67984. doi: 10.1371/journal.pone.0067984 PMID:23785523
47. Melamed S, Wyatt LS, Kastenmayer LJ, Moss B. Attenuation and immunogenicity of host-range extended modified vaccinia virus Ankara recombinants. Vaccine 2013; 31: 4569–77. doi:10.1016/j.vaccine.2013.07.057 PMID: 23785523
48. Liu L, Zhong Q, Tian T, Dubin K, Athale SK, Kupper TS. Epidermal injury and infection during poxvirus immunization is crucial for the generation of highly protective T cell-mediated immunity. Nat Med 2010; 16: 224–7. doi: 10.1038/nm.2078 PMID: 20081864
49. Carey JB, Pearson FE, Vrdoljak A, McGrath MG, Crean AM, Walsh PT, et al. Microneedle array design determines the induction of protective memory CD8+ T cell responses induced by a recombinant live malaria vaccine in mice. PLoS One 2011; 6: e22442. doi: 10.1371/journal.pone.0022442 PMID: 21799855
50. Pearson FE, McNeilly CL, Crichton ML, Primiero CA, Yukiko SR, Fernando GJ, et al. Dry-coated live viral vector vaccines delivered by nanopatch microprojections retain long-term thermostability and induce transgene-specific T cell responses in mice. PLoS One 2013; 8: e67888. doi: 10.1371/journal.pone.0067888 PMID: 23874462
51. Meseda CA, Elkins KL, Merchlinsky MJ, Weir JP. Prime-boost immunization with DNA and modified vaccinia virus ankara vectors expressing herpes simplex virus-2 glycoprotein D elicits greater specific antibody and cytokine responses than DNA vaccine alone. J Infect Dis 2002; 186: 1065–73. PMID:12355355
52. Chakrabarti S, Sisler JR, Moss B. Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques 1997; 23:1094–97. PMID:9421642
53. Schmeisser F, Adamo JE, Blumberg B, Friedman R, Muller J, Soto J, Weir JP. Production and characterization of mammalian virus-like particles from modified vaccinia virus Ankara vectors expressing influenza H5N1 hemagglutinin and neuraminidase. Vaccine 2012; 30: 3413–22. doi: 10.1016/j.vaccine.2012.03.033 PMID: 22465746
54. Earl PL, Cooper N, Wyatt LS, Moss B. Preparation of cell cultures and vaccinia virus stocks. In: Ausubel FM, Brent R, Kingston RE, et al., editors. Current protocols in molecular biology. New York, NY: John Wiley & Sons, Inc. 2001; doi:10.1002/0471140864.ps0512s13
55. Rowe T, Abernathy RA, Hu-Primmer J, Thompson WW, Lu X, Lim W, et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999; 37: 937–43. PMID:10074505
56. Volz A, Kupke A, Song F, Jany S, Fux R, Shams-Eldin H, et al. Protective efficacy of recombinant modified vaccinia virus Ankara delivering Middle East respiratory coronavirus spike glycoprotein. J Virol 2015; 89: 8651–6. doi:10.1128/JVI.00614-15 PMID:26918172
57. Wilck MB, Seaman MS, Baden LR, Walsh SR, Grandpre LE, Devoy C, et al. Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration. J Infect Dis 2010; 201: 1361–70. doi:10.1086/651561 PMID:20350191
58. Zitzmann-Roth EM, von Sonnenburg F, de la Motte S, Arndtz-Wiedemann N, von Krempelhuber A, Uebler N, et al. Cardiac safety of Modified Vaccinia Ankara for vaccination against smallpox in a young, healthy study population. PLoS One 2015; 10: e0122653. doi: 10.1371/journal.pone.0122653 PMID: 25879867
59. Busquets N, Lorenzo G, Lopez-Gil E, Rivas R, Solanes D, Galindo-Cardiel I, et al. Efficacy assessment of an MVA vectored Rift Valley Fever vaccine in lambs. Antiviral Res 2014; 108: 165–72. doi:10.1016/j.antiviral.2014.05.020 PMID:24930081
60. Amato RJ, Stepankiv M. Evaluation of MVA-5T4 as a novel immunotherapeutic vaccine in colorectal, renal and prostate cancer. Future Oncol 2012; 8: 231–7. doi: 10.2217/fon.12.7 PMID: 22409460
61. Kennedy RB, Ovsyannikova I, Poland GA. Smallpox vaccines for biodefense. Vaccine 2009; 27: D73–9. doi:10.1016/j.vaccine.2009.07.103 PMID: 19837292
62. Rice AD, Adams MM, Lindsey SF, Swetnam DM, Manning BR, Smith AJ, et al., Protective properties of vaccinia virus-based vaccines: skin scarification promotes a nonspecific immune response that protects against orthopoxvirus disease. J Virol 2014; 88: 7753–63. doi:10.1128/JVI.00185-14 PMID: 24760985
63. Peters BS, Jaoko W, Vardas E, Panayotakopoulos G, Fast P, Schmidt C, et al. Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity. Vaccine 2007; 25: 2120–27. PMID: 17250931

64. Meyer J, Harris SA, Satti I, Poulton ID, Poyntz HC, Tanner R, et al. Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery. Vaccine 2013; 31: 1026–33. doi: 10.1016/j.vaccine.2012.12.042 PMID: 23266342

65. Al-Zahrani S, Zoric M, McCrudden C, Scott C, Kissenpfennig A, Donnelly RF. Microneedle-mediated vaccine delivery: harnessing cutaneous immunobiology to improve efficacy. Expert Opin Drug Deliv 2012; 9: 541–50. doi: 10.1517/17425247.2012.676038 PMID: 22475249

66. Hawkridge A, Hatherill M, Little F, Goetz MA, Barker L, Mahomed H, et al. Efficacy of percutaneous versus intradermal BCG in the prevention of tuberculosis in South African infants: randomised trial. BMJ 2008; 337: a2052. doi: 10.1136/bmj.a2052 PMID: 19008268

67. Edens C, Dybdahl-Sissoko NC, Weldon WC, Oberste MS, Prausnitz MR. Inactivated polio vaccination using a microneedle patch is immunogenic in the rhesus macaque. Vaccine 2015; 33: 4683–90. doi: 10.1016/j.vaccine.2015.01.089 PMID: 25749246

68. Koutsonanos DG, Esser ES, McMaster SR, Kalluri P, Lee JW, Prausnitz MR, et al. Enhanced immune responses by skin vaccination with influenza subunit vaccine in young hosts. Vaccine 2015; 33: 4675–82. doi: 10.1016/j.vaccine.2015.01.086 PMID: 25744228

69. Koutsonanos DG, Vassilieva EV, Stavropoulou A, Zarnitsyn VG, Esser ES, Taherhadi MT, et al. Delivery of subunit influenza vaccine to skin with microneedles improves immunogenicity and long-lived protection. Sci Rep 2012; 2: 357. doi: 10.1038/srep00357 PMID: 22500210

70. Quan FS, Kim YC, Companos RW, Prausnitz MR, Kang SM. Dose sparing enabled by skin immunization with influenza virus-like particle vaccine using microneedles. J Control Release 2010; 147: 326–32. doi: 10.1016/j.jconrel.2010.07.125 PMID: 20692307

71. Edens C, Collins ML, Ayers J, Rota PA, Prausnitz MR. Measles vaccination using a microneedle patch. Vaccine 2013; 31: 3403–9. doi: 10.1016/j.vaccine.2012.09.062 PMID: 23440406

72. Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM., Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 2004; 351: 2295–301. PMID: 15525714

73. Belshes RB, Newman FK, Wilkins K, Graham IL, Babusis E, Ewell M, Frey SE. Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults. Vaccine 2007; 25: 6755–63. PMID: 17692438

74. Vien FC, Ferolli E, Lang J. Long-term anti-rabies antibody persistence following intramuscular or low-dose intradermal vaccination of young Vietnamese children. Trans R Soc Trop Med Hyg 2008; 102: 294–6. doi: 10.1016/j.trstmh.2007.11.010 PMID: 18191971

75. Li J, Clark RA, Liu L, Wagers AJ, Fuhlinger RC, Kupper TS. Skin infection generates non-migratory memory CD8+ T(RM) cells providing global skin immunity. Nature 2012; 483: 227–31. doi: 10.1038/nature10851 PMID: 22388819

76. Becker PD, Hervouet C, Mason GM, Kwon SY, Klavinsks LS. Skin vaccination with live virus vectored microneedle arrays induce long-lived CD8+ T cell memory. Vaccine 2015; 33: 4691–8. PMID: 25917679

77. Frey SE, Wald A, Edupuganti S, Jackson LA, Stapleton JT, Sahly HE, et al. Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naive subjects. Vaccine 2015; 33: 5225–34. PMID: 26143613

78. Drexler I, Staib C, Sutter G. Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential? Curr Opin Biotechnol 2004; 15: 506–12. PMID: 15560976

79. Rimmelzwaan GF, Sutter G. Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara. Expert Rev Vaccines 2009; 8: 447–54. doi: 10.1586/erv.09.4 PMID: 19348560

80. Kreijtz JH, Suezer Y, van Amerongen G, de Mutsert G, Schnirle BS, Wood JM, et al. Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1. J Infect Dis. 2007; 195: 1598–606. PMID: 17471429

81. Poon LL, Leung YH, Nicholls JM, Perera PY, Lichy JH, Yamamoto M, et al. Vaccinia virus-based multivalent H5N1 avian influenza vaccines adjuvanted with IL-15 confer sterile cross-clade protection in mice. J Immunol 2009; 182: 3063–71. doi: 10.4049/jimmunol.0803467 PMID: 19234203

82. Hessel A, Schwendinger M, Holzer GW, Orlinger KK, Coulialby S, Savidis-Dacho H, et al. Vectors based on modified vaccinia Ankara expressing influenza H5N1 hemagglutinin induce substantial cross-clade protective immunity. PLoS One. 2011; 6: e16247. doi: 10.1371/journal.pone.0016247 PMID: 21283631
83. Kamlangdee A, Kingstad-Bakke B, Anderson TK, Goldberg TL, Osorio JE. Broad protection against avian influenza virus by using a modified vaccinia Ankara virus expressing a mosaic hemagglutinin gene. J Virol. 2014; 88:13300–09. doi:10.1128/JVI.01532-14 PMID: 25210173

84. Kreijtz JH, Süzer Y, Bodewes R, Schwantes A, van Amerongen G, Verburgh RJ, et al. Evaluation of a modified vaccinia virus Ankara (MVA)-based candidate pandemic influenza A/H1N1 vaccine in the ferret model. J Gen Virol. 2010; 91: 2745–52. doi:10.1099/vir.0.024885-0 PMID: 20719991

85. Kreijtz JH, Suezer Y, de Mutsert G, van den Brand JM, van Amerongen G, Schnierle BS, et al. Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses. Vaccine 2009; 27: 6296–99. PMID:19840663

86. Florek NW, Weinfurter JT, Jegaskanda S, Brewoo JN, Powell TD, Young GR, et al. Modified vaccinia virus Ankara encoding influenza virus hemagglutinin induces heterosubtypic immunity in macaques. J Virol 2014; 88: 13418–28. doi:10.1128/JVI.01219-14 PMID: 25210172

87. Gill HS, Prausnitz MR. Coated microneedles for transdermal delivery. J Control Release 2007; 117: 227–37. PMID: 17169459

88. Prausnitz MR, Mikesza JA, Cormier M, Andrianov AK. Microneedle-based vaccines. Curr Top Microbiol Immunol 2009; 333: 369–93. doi:10.1007/978-3-540-92165-3_18 PMID: 19768415

89. Vrdoljak A, McGrath MG, Carey JB, Draper SJ, Hill AV, O’Mahony C, et al. Coated microneedle arrays for transcutaneous delivery of live virus vaccines. J Control Release 2012; 159: 34–42. doi:10.1016/j.jconrel.2011.12.026 PMID: 22245683

90. Carey JB, Pearson FE, Vrdoljak A, McGrath MG, Crean AM, Walsh PT, et al. Microneedle array design determines the induction of protective memory CD8+ T cell responses induced by a recombinant live malaria vaccine in mice. PLoS One 2011; 6: e22442. doi:10.1371/journal.pone.0022442 PMID: 21799855